Drug Profile

TTX 330

Alternative Names: TTX-300-Evitar; TTX-330; TTX-330-Spinal

Latest Information Update: 02 Feb 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Temple Therapeutics
Class Amino acids; Anti-inflammatories; Antifibrotics
Mechanism of Action Immunomodulators; Transforming growth factor beta3 modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

02 Feb 2023 Preclinical trials in Frozen shoulder in Netherlands (unspecified route) (Temple Therapeutics pipeline; January 2023)
28 Jun 2022 No recent reports of development identified for preclinical development in Epidural-fibrosis in Netherlands
30 May 2018 Preclinical trials in Epidural fibrosis in Netherlands (unspecified route) before May 2018 (Temple Therapeutics Pipeline, May 2018)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com